| scholarly article | Q13442814 |
| P2093 | author name string | P. Bollinger | |
| P. C. Hiestand | |||
| J. A. Laissue | |||
| H. J. Altermatt | |||
| G. Poschmann | |||
| K. Nooter | |||
| R. P. Keller | |||
| P2860 | cites work | Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives | Q36467823 |
| Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma | Q41144143 | ||
| Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins | Q41812714 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| cyclosporine | Q367700 | ||
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 593-597 | |
| P577 | publication date | 1992-02-01 | |
| 1992-02-20 | |||
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia | |
| P478 | volume | 50 |
| Q40591949 | A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). |
| Q34768677 | A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. |
| Q43865028 | Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes |
| Q40883320 | Breast cancer therapies in development. A review of their pharmacology and clinical potential. |
| Q38871364 | Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach |
| Q40708934 | Cellular models for multiple drug resistance in cancer |
| Q40596146 | Cellular resistance to cancer chemotherapy. |
| Q54187619 | Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. |
| Q41337252 | Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. |
| Q41987358 | Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells |
| Q36054864 | Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. |
| Q36134341 | Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia |
| Q44027605 | Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy |
| Q41570003 | Drug metabolism: from experiments to regulatory aspects |
| Q107033036 | Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 |
| Q107033464 | Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 |
| Q73497880 | Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine |
| Q42491250 | Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo |
| Q36431370 | Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. |
| Q42107137 | Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. |
| Q40271710 | Future perspectives for the development of P-glycoprotein modulators |
| Q77737834 | High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma |
| Q41734226 | In vivo model systems in P-glycoprotein-mediated multidrug resistance |
| Q41214653 | In vivo pharmacological effects of ciclosporin and some analogues |
| Q54115530 | Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. |
| Q41506000 | Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: Comparison with other chemosensitisers |
| Q54084308 | Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. |
| Q40978951 | Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein |
| Q42651277 | Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist |
| Q71876211 | Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice |
| Q41564063 | Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action? |
| Q33758413 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) |
| Q73429640 | Modulation of Multidrug Resistance in Cancer by Immunosuppresive Agents. Preclinical Studies |
| Q38309352 | Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles |
| Q70558140 | Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity |
| Q55043110 | Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. |
| Q34060806 | Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs |
| Q40650383 | Multidrug resistance reversal activity of key ningalin analogues |
| Q73133154 | Mutually co-operative interactions between modulators of P-glycoprotein |
| Q73481268 | P-glycoprotein expression in cartilaginous tumors |
| Q45871082 | P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells |
| Q39998933 | Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein |
| Q33929477 | Promising approaches in acute leukemia |
| Q77973909 | Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative |
| Q54220488 | Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity. |
| Q73038137 | The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts |
| Q49909701 | U-box ubiquitin ligase PPIL2 suppresses breast cancer invasion and metastasis by altering cell morphology and promoting SNAI1 ubiquitination and degradation |
| Q48826637 | Valspodar: current status and perspectives |
Search more.